# A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability

> **NCT00517543** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)
- Rheumatoid Arthritis
- Atherosclerosis

## Interventions

- **DRUG:** GW856553

## Key facts

- **NCT ID:** NCT00517543
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2010-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517543, "A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT00517543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*